Literature DB >> 36121476

Stress-inducible phosphoprotein 1 (HOP/STI1/STIP1) regulates the accumulation and toxicity of α-synuclein in vivo.

Rachel E Lackie1,2, Aline S de Miranda1,3, Mei Peng Lim1,2, Vladislav Novikov1,2, Nimrod Madrer4, Nadun C Karunatilleke5, Benjamin S Rutledge5, Stephanie Tullo6, Anne Brickenden5, Matthew E R Maitland1,5, David Greenberg4, Daniel Gallino6, Wen Luo7, Anoosha Attaran1, Irina Shlaifer7, Esther Del Cid Pellitero7, Caroline Schild-Poulter1,5, Thomas M Durcan7, Edward A Fon7, Martin Duennwald8, Flavio H Beraldo1, M Mallar Chakravarty6, Timothy J Bussey1,2,9, Lisa M Saksida1,2,9, Hermona Soreq4, Wing-Yiu Choy10, Vania F Prado11,12,13,14, Marco A M Prado15,16,17,18.   

Abstract

The predominantly pre-synaptic intrinsically disordered protein α-synuclein is prone to misfolding and aggregation in synucleinopathies, such as Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). Molecular chaperones play important roles in protein misfolding diseases and members of the chaperone machinery are often deposited in Lewy bodies. Here, we show that the Hsp90 co-chaperone STI1 co-immunoprecipitated α-synuclein, and co-deposited with Hsp90 and Hsp70 in insoluble protein fractions in two mouse models of α-synuclein misfolding. STI1 and Hsp90 also co-localized extensively with filamentous S129 phosphorylated α-synuclein in ubiquitin-positive inclusions. In PD human brains, STI1 transcripts were increased, and in neurologically healthy brains, STI1 and α-synuclein transcripts correlated. Nuclear Magnetic Resonance (NMR) analyses revealed direct interaction of α-synuclein with STI1 and indicated that the STI1 TPR2A, but not TPR1 or TPR2B domains, interacted with the C-terminal domain of α-synuclein. In vitro, the STI1 TPR2A domain facilitated S129 phosphorylation by Polo-like kinase 3. Moreover, mice over-expressing STI1 and Hsp90ß presented elevated α-synuclein S129 phosphorylation accompanied by inclusions when injected with α-synuclein pre-formed fibrils. In contrast, reduced STI1 function decreased protein inclusion formation, S129 α-synuclein phosphorylation, while mitigating motor and cognitive deficits as well as mesoscopic brain atrophy in α-synuclein-over-expressing mice. Our findings reveal a vicious cycle in which STI1 facilitates the generation and accumulation of toxic α-synuclein conformers, while α-synuclein-induced proteostatic stress increased insoluble STI1 and Hsp90.
© 2022. The Author(s).

Entities:  

Keywords:  A53T; Chaperone; HOP; Hsp70; Hsp90; Lewy body; Neuropathology; Parkinson’s; Pre-formed fibrils; STIP1; Touchscreens; α-Synuclein

Mesh:

Substances:

Year:  2022        PMID: 36121476      PMCID: PMC9547791          DOI: 10.1007/s00401-022-02491-8

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   15.887


  129 in total

1.  In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.

Authors:  M Bergeron; R Motter; P Tanaka; D Fauss; M Babcock; S-S Chiou; S Nelson; F San Pablo; J P Anderson
Journal:  Neuroscience       Date:  2013-10-12       Impact factor: 3.590

2.  α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.

Authors:  Youngshin Lim; Victoria M Kehm; Edward B Lee; James H Soper; Chi Li; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

3.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies.

Authors:  Kunihiro Uryu; Christiane Richter-Landsberg; William Welch; Eveline Sun; Olaf Goldbaum; Erin H Norris; Chi-Tuan Pham; Ikuru Yazawa; Kristen Hilburger; Matthew Micsenyi; Benoit I Giasson; Nancy M Bonini; Virginia M-Y Lee; John Q Trojanowski
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

5.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

6.  The touchscreen operant platform for assessing executive function in rats and mice.

Authors:  Adam C Mar; Alexa E Horner; Simon R O Nilsson; Johan Alsiö; Brianne A Kent; Chi Hun Kim; Andrew Holmes; Lisa M Saksida; Timothy J Bussey
Journal:  Nat Protoc       Date:  2013-09-19       Impact factor: 13.491

Review 7.  Protein Quality Control by Molecular Chaperones in Neurodegeneration.

Authors:  Aaron Ciechanover; Yong Tae Kwon
Journal:  Front Neurosci       Date:  2017-04-06       Impact factor: 4.677

8.  HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies.

Authors:  Anastasiia Bohush; Grażyna Niewiadomska; Serge Weis; Anna Filipek
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

9.  The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.

Authors:  Anne-Laure Mahul-Mellier; Johannes Burtscher; Niran Maharjan; Laura Weerens; Marie Croisier; Fabien Kuttler; Marion Leleu; Graham W Knott; Hilal A Lashuel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-19       Impact factor: 11.205

10.  Subtle alterations in neonatal neurodevelopment following early or late exposure to prenatal maternal immune activation in mice.

Authors:  Elisa Guma; Emily Snook; Shoshana Spring; Jason P Lerch; Brian J Nieman; Gabriel A Devenyi; M Mallar Chakravarty
Journal:  Neuroimage Clin       Date:  2021-10-29       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.